JAK2 and essential thrombocythemia: Studies of ET patients have shown that, compared with CALR‐variants or triple‐negative cases, JAK2 V617F platelets have the lowest αIIbβ3 activation and P‐selectin expression in response to agonists, though whether this translates to an increased thrombohaemorrhagic outcome is less certain [38].